CYP19A1
ENSG00000137869
Target class
Enzyme
Chromosome
15
Approved drugs
5
Clinical candidates (approved and in development)
5
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- CYP19A1
- Gene name
- Cytochrome P450 family 19 subfamily A member 1
- Gene symbol
- CYP19A1
- Previous gene symbols
- CYP19
- Protein name
- Aromatase (EC 1.14.14.14) (CYPXIX) (Cytochrome P-450AROM) (Cytochrome P450 19A1) (Estrogen synthase)
- ARO
- P-450AROM
- CPV1
- ARO1
- CYAR
- aromatase
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 19|MicroRNA protein coding host genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 5
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 7.61
- Tissue specificity (Gini)
- 0.751
- Tissue specificity (tau)
- 0.956
- KEGG gene identifiers
- hsa:1588
- Protein interaction confidence
- 0.883477
- Protein interaction partners
- 65
- R-HSA-193144
- R-HSA-211976
- R-HSA-5579030
- End position
- 51338601
- Start position
- 51208057
- Chromosome
- 15
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Multi-pass membrane protein . Microsome membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 2973313
- Tissue specificity (tau)
- 0.955743
- Expression inequality (Gini)
- 0.751142
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 7.61
- Nerve - Tibial
- 3.42
- Testis
- 2.67
- Adipose - Subcutaneous
- 2.18
- Thyroid
- 1
Expression in transcripts per million
- Cells - Cultured fibroblasts7.61
- Nerve - Tibial3.42
- Testis2.67
- Adipose - Subcutaneous2.18
- Thyroid1
- Ovary0.75
- Artery - Coronary0.72
- Skin - Sun Exposed (Lower leg)0.47
- Bladder0.47
- Artery - Tibial0.39
- Adrenal Gland0.35
- Adipose - Visceral (Omentum)0.35
- Breast - Mammary Tissue0.34
- Cervix - Endocervix0.34
- Spleen0.31
- Artery - Aorta0.28
- Cervix - Ectocervix0.28
- Heart - Atrial Appendage0.28
- Vagina0.27
- Skin - Not Sun Exposed (Suprapubic)0.26
- Minor Salivary Gland0.24
- Brain - Spinal cord (cervical c-1)0.23
- Lung0.23
- Fallopian Tube0.21
- Esophagus - Muscularis0.19
And 29 more, listed on the interactive page.
- GO:0006694
- GO:0006703
- GO:0006710
- GO:0016125
- GO:2000866
- GO:0005783
- GO:0005789
- GO:0016020
- GO:0008395
- GO:0009055
- GO:0016712
- GO:0019825
- GO:0020037
- GO:0070330
- GO:0101021
Reduction, Cumulative fecundity and spawning
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceDecreased fertility, Reduced number of oocytes ovulated
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- ovary growing follicle
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceReduction, Cumulative fecundity and spawning
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- ovary growing follicle
Evidence source
regulation of catalytic activity
Studies
- biochemical: NVS_ADME_hCYP19A1, is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP19A1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.
Biological samples
- cell-free
Evidence sourceregulation of transcription factor activity
Studies
- cell-based: TOX21_Aromatase_Inhibition, is one of one assay component(s) measured or calculated from the TOX21_Aromatase_Inhibition assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.
Biological samples
- MCF-7, cell line
Evidence source
Related records
Trials (1,115)
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
- 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
- A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
- A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted
- A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
- A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity
- A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Comparison of Letrozole and Clomifene Citrate
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
- A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
- A New Oral Treatment For Type II Diabetes Mellitus
- A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Drugs (6)
- Aminoglutethimide Cytochrome P450 19A1 inhibitor
- Anastrozole Cytochrome P450 19A1 inhibitor
- Exemestane Cytochrome P450 19A1 inhibitor
- Fadrozole Cytochrome P450 19A1 inhibitor
- Letrozole Cytochrome P450 19A1 inhibitor
- Testolactone Cytochrome P450 19A1 inhibitor